Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPlastic/Reconstructive SurgeryAetna Breast Reduction Gynecomastia Coverage Updat…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0017

    Breast Reduction Surgery and Gynecomastia Surgery

    Customize your policy alerts

    Sign up for Aetna Policy 0017 alerts

    Get alerted when Policy 0017 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Aetna's medical necessity, cosmetic, and investigational coverage stance for reduction mammoplasty and gynecomastia procedures, and lists related codes and background evidence; applies to members under Aetna plans.

    Policy Summary
    PayerAetna
    PolicyBreast Reduction Surgery and Gynecomastia Surgery
    Policy CodePolicy 0017
    Change TypeNo material changes
    Effective DateOct 6, 1995
    Last ReviewMar 6, 2023
    Next Review DateJan 11, 2024
    Key ActionObtain prior authorization and document BSA-based estimated tissue weight and at least a 3-month trial of conservative therapies before reduction mammoplasty.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    >60,000annual US procedures (lit.)
    >=3 monthsconservative therapy trial
    1 kg1 kg per breast threshold
    60-70%adolescent transient gynecomastia
    5.1%overall surgical complication rate
    ~92references cited

    Coverage Criteria for Reduction Mammoplasty and Gynecomastia Surgery

    Macromastia (Reduction Mammoplasty) Medical Necessity

    Covered when ALL of the following are met for macromastia

    Symptom requirement: Member has persistent symptoms in at least two anatomical areas (headaches; neck pain; shoulder pain; upper back pain; painful kyphosis documented by X-ray; bra-strap related discomfort or pain/ulceration from straps; skin breakdown including severe soft-tissue infection, tissue necrosis, ulceration or hemorrhage; or upper extremity paresthesia) affecting daily activities for at least 1 year>=2 areas; >=1 year

    Supported by physician documentation and attribution to macromastia

    Severity and documentation: All of: severe breast hypertrophy documented by high-quality color frontal-view and side-view photographs; reasonable likelihood that symptoms are primarily due to macromastia; and reduction mammoplasty is likely to result in improvement of the chronic painphotographs required
    Policy Summary
    PayerAetna
    PolicyBreast Reduction Surgery and Gynecomastia Surgery
    Policy CodePolicy 0017
    Change TypeNo material changes
    Effective DateOct 6, 1995
    Last ReviewMar 6, 2023
    Next Review DateJan 11, 2024
    Key ActionObtain prior authorization and document BSA-based estimated tissue weight and at least a 3-month trial of conservative therapies before reduction mammoplasty.
    SourceLink
    On This Page
    Coverage Criteria for Reduction Mammoplasty and Gynecomastia SurgeryCoding and Quantitative ThresholdsProvider Actions, Authorization & Documentation RequirementsBackground and ContextDefinitions and ScalesPolicy Revision History
    Conservative therapy trial: Pain symptoms persist despite at least a 3-month trial of therapeutic measures such as analgesics/NSAIDs and/or muscle relaxants; dermatologic therapy for ulcers/necrosis/refractory infection; physical therapy/exercises/posturing; supportive devices (eg, proper bra support, wide straps); chiropractic or osteopathic manipulative treatment; medically supervised weight loss; and orthopedic/spine evaluation as indicated>=3 months

    List of acceptable conservative therapies provided

    Imaging and age-specific requirement: Women 50 years of age or older must have a negative mammogram performed within the 2 years prior to the planned reduction mammoplastymammogram within 2 years for age >=50
    Tissue removal estimate: Surgeon documents estimated grams of breast tissue (non‑fatty tissue) to be removed from each breast based on the member's body surface area (Mosteller formula) using the Appendix Table; note: if >1 kg of breast tissue is to be removed per breast, medical necessity criteria are met regardless of BSABSA-based grams OR >1 kg per breast

    Appendix Table 1 referenced for gram thresholds

    Gigantomastia of Pregnancy

    Covered when ANY of the listed serious complications are present and delivery is not imminent

    Pregnancy complications: Massive infection OR significant hemorrhage OR tissue necrosis with slough OR ulceration of breast tissueany one of listed complications

    Delivery must not be imminent

    Effectiveness of reduction mammoplasty for pain relief

    Evidence summary and general conclusion

    Evidence quality conclusion: Well-designed prospective controlled trials are lacking; studies supporting effectiveness for relieving chronic back, neck, or shoulder pain are poorly controlled and subject to bias. Therefore evidence is insufficient to support reduction mammoplasty, irrespective of breast size or resection amount, solely for relieving chronic back, neck, or shoulder pain.

    Based on critical appraisal of published studies including lack of prospective controlled trials

    Age and breast maturity guidance

    Timing considerations for adolescents

    Timing: Delay reduction mammoplasty until breast growth has ceased and breast size has been stable for at least 12 months; average final breast maturity occurs around age 15 but individual variation existsstable for >= 12 months

    Cites ASPS/ACOG guidance and surgical texts

    Perioperative risk factors and counseling

    Risk stratification for perioperative complications

    Risk factors linked to increased complications: Morbid obesity (including BMI > 40 kg/m2), active smoking, dyspnea, resident participation, inpatient surgery, higher resection weight, and older age are independently associated with increased surgical complications and should be considered in patient selection and counselingBMI >40; active smoker

    Quantified by NSQIP and cohort analyses (odds ratios and increased complication rates)

    Use of postoperative drains

    Adjunctive surgical practices

    Drain use evidence: Randomized trials and a Cochrane review found no significant benefit to routine use of postoperative wound drains after reduction mammoplasty (no impact on complications), though length of stay may be shorter without drains; when liposuction is used as an adjunct, drain use may be left to the surgeon's discretion

    Based on Cochrane review and related practice survey

    Evaluation and indications for gynecomastia surgery

    Gynecomastia management pathway

    Work-up before surgery: Evaluation should include detailed medication and environmental exposure history; testicular and physical examination; liver and thyroid function tests; hormonal assays (gonadotropins, hCG, testosterone, estradiol, DHEAS); testicular ultrasound and adrenal imaging as indicated; reversible causes should be corrected and conservative/medical management considered (pubertal cases often resolve within 18 months) before elective surgeryresolve within 18 months typical for pubertal cases

    Medical therapy (eg, tamoxifen) can be effective and surgery is rarely indicated unless medical causes excluded or medical/supervised therapy fails

    Evidence summaries and practice implications

    Summary of clinical evidence and indications reported:

    General: Gynecomastia can have substantial psychological impact and surgical treatment may improve quality of life and psychological domains when medical treatments fail; however, overall quality of evidence is low and further robust studies are needed

    Supported by systematic reviews and cohort studies reporting psychological benefit and limitations in evidence quality

    Minimally invasive options: Vacuum-assisted breast biopsy systems have been reported as feasible, safe, and cosmetically satisfactory in small series and cohort studies as a minimally invasive alternative to open surgery in selected patients

    Preliminary evidence (small retrospective/level IV series) requires validation

    Liposuction-assisted techniques: Liposuction-assisted gynecomastia techniques report improved patient satisfaction and QOL in multiple small series, but study heterogeneity and generally low methodological quality limit firm conclusions about comparative effectiveness and complication rates

    Systematic reviews note inconsistent complication and re-operation rates

    Adolescents: Adolescent reduction mammaplasty is associated with moderate overall complication rates and counseling should address potential for breast regrowth (~18%) and variable breastfeeding outcomes (about 55% success among those who attempted)

    Pooled analysis of adolescent series

    Previously irradiated breast: Reduction mammoplasty or mastopexy in previously irradiated breasts is associated with markedly higher complication rates (eg, 54% vs 8% in non-irradiated breasts) and requires careful patient selection and counseling

    Meta-analysis reported rate ratio ~4.82

    Radiotherapy prophylaxis: Low-dose radiotherapy (8–16 Gy over 1–11 fractions) reduces incidence of gynecomastia in high-risk populations (eg, prostate cancer patients on estrogen/anti-androgen therapy) with primarily minor, self-limited complications

    Systematic review of 15 articles

    The policy lists several supplemental coverage notes relevant to alternate techniques and adjunctive interventions. Liposuction-only reduction mammoplasty is classified as experimental and investigational and therefore not covered. [[6]]

    For gynecomastia management, radiotherapy (for prevention or management of recurrence) and vacuum-assisted breast biopsy systems for treatment of gynecomastia are also considered experimental and investigational and not covered. [[6]]

    Vacuum-assisted minimally invasive approaches and vacuum-assisted biopsy systems are described in the evidence summary as reported in small cohorts with favorable cosmetic outcomes, but the policy’s coverage stance treats vacuum-assisted biopsy systems for treatment of gynecomastia as investigational. Providers should note this distinction between reported feasibility in small series and the formal noncoverage classification. [[39]]

    Procedures performed solely for cosmetic reasons are excluded. Specifically, breast reduction surgery for cosmetic indications — including gynecomastia procedures performed when medical selection criteria are not met — is considered cosmetic and not covered. [[6]]

    The policy also explicitly states that reduction mammoplasty for asymptomatic members is considered cosmetic and therefore excluded from coverage. Documentation should demonstrate symptomatic criteria before authorization is approved. [[5]]

    The policy concludes that available studies are poorly controlled and subject to bias; therefore there is insufficient evidence to support reduction mammoplasty solely as a treatment for chronic back, neck, or shoulder pain irrespective of breast size or resection amount. High-quality prospective controlled trials are lacking. [[20]]

    Similarly, for gynecomastia, surgical correction is characterized in pediatric/adolescent reviews as an elective intervention and the policy highlights that evidence does not clearly demonstrate superiority of surgery over conservative management for pain from gynecomastia. These evidence limitations inform the policy’s conservative coverage approach. [[34]]

    Systematic reviews and series of liposuction-assisted gynecomastia techniques frequently have low methodological quality (Level of Evidence III) with small sample sizes, limited patient detail, inconsistent reporting of complications and satisfaction, and risk of selection and reporting bias. These limitations restrict confidence in conclusions about effectiveness and safety. [[51]]

    The appendix provides a comprehensive list of drugs and exposures associated with gynecomastia that should be considered during evaluation. Categories and examples include estrogens and estrogen-like drugs (e.g., diethylstilbestrol, estrogen-containing topical products), agents that enhance estrogen formation (e.g., hCG), drugs that inhibit testosterone synthesis (e.g., ketoconazole, spironolactone, certain chemotherapies), drugs that inhibit testosterone action (e.g., bicalutamide, finasteride, marijuana), and multiple agents with unknown mechanisms (e.g., tricyclic antidepressants, ACE inhibitors, amiodarone). The list also notes anabolic steroids and topical products containing lavender or tea tree oil as possible causes. [[55]]

    Chronic intertrigo, eczema, dermatitis, and/or ulceration confined to the inframammary fold alone do not meet criteria for reduction mammoplasty. These dermatologic conditions must be refractory to dermatologic treatments and conservative measures for at least 6 months and the member must otherwise satisfy the macromastia criteria for surgery to be considered medically necessary. [[5]]

    The evidence base for reduction mammoplasty providing durable pain relief is limited by poor study design and bias; consequently the policy states there is insufficient high-quality evidence to support performing reduction mammoplasty for pain relief when functional impairment criteria are not met. [[20]]

    Similarly, surgical correction of gynecomastia in the absence of functional impairment is generally considered elective; the literature review characterizes many gynecomastia surgeries as cosmetic interventions when medical therapy or conservative management has not been exhausted. [[34]]

    The policy notes that methodological limitations and low-quality evidence identified in the literature do not by themselves constitute explicit non-coverage statements within the document excerpt. Instead, these limitations inform the policy’s determinations and the conservative framing of indications, but the text distinguishes evidence gaps from formal not-medically-necessary language. [[51]]

    Providers should interpret statements about low-quality or biased studies as rationale for cautious application of selection criteria rather than as standalone coverage denials absent the policy’s explicit exclusion language. [[20]]

    Coding and Quantitative Thresholds

    Covered CPT Codes (if selection criteria met)CPTCovered
    19318Reduction mammaplasty
    CPT Codes not covered for listed indications / related codesCPTNot Covered
    15877Suction assisted lipectomy; trunk
    Other related CPT CodesCPT
    19300Mastectomy for gynecomastia
    19301Mastectomy, partial (e.g., lumpectomy)
    19316Mastopexy
    Imaging CPT CodesCPT
    77065-77067Diagnostic mammography, including computer-aided detection (CAD) when performed
    HCPCS Codes (not covered)HCPCSNot Covered
    G6003-G6014Radiation treatment delivery
    G6015-G6016IMRT treatment delivery
    ICD-10 Diagnosis Codes (covered if selection criteria met)ICD-10Covered
    G56.00-G56.93Mononeuropathies of upper limb [upper extremity paresthesia]
    I96Gangrene, not elsewhere classified [tissue necrosis]
    L98.491-L98.494Non-pressure chronic ulcer of skin of other sites
    N62Hypertrophy of breast [symptomatic-causing significant pain, paresthesias, or ulceration]
    N64.89Other specified disorders of breast [soft tissue infection]
    Referenced CPT code in outcome analysesCPT
    19318Reduction mammoplasty (CPT code cited in NSQIP dataset analysis)
    inv-24: Estimated tissue removal per breast — surgeon estimates grams by BSA; >1 kg per breast considered medically necessary regardless of BSA
    Surgeon estimate methodSurgeon estimates grams to be removed per breast using body surface area (BSA) calculated by the Mosteller formula
    BSA-based thresholdIf estimated removal meets or exceeds the BSA-based gram amounts from Appendix Table 1, criteria for tissue removal are satisfied
    >1 kg exceptionNote: breast reduction is considered medically necessary regardless of BSA if more than 1 kg (1000 g) of breast tissue will be removed per breast
    Documentation requirementSurgeon must document the estimated grams to be removed per breast in preoperative documentation
    Reference for tableAppendix Table 1 provides the BSA-to-grams mapping used for these estimates
    inv-25: BMI — Class III (BMI > 40) associated with higher postoperative wound complications
    BMI risk classClass III obesity (BMI > 40 kg/m2) is associated with significantly higher postoperative wound complications
    Obesity and complicationsIncreasing obesity class is associated with increased early postoperative complications; morbidly obese patients had nearly 12% complication rate in one analysis
    Evidence sourcesFindings reported in population-level NSQIP analyses and cohort studies assessing BMI impact on wound and early complications
    Consideration for authorizationBMI should be considered when assessing surgical risk and counseling patients prior to reduction mammoplasty
    inv-26: Smoking status — Active smoking associated with increased major and overall surgical complications
    Smoking increases major complicationsActive smoking is independently associated with increased major surgical morbidity (e.g., OR 2.7 for major complications in NSQIP analysis)
    Smoking and overall complicationsActive smoking was associated with higher odds of any surgical complication (OR 1.7) and higher reoperation rates
    Authorization implicationSmoking status should be assessed and documented during authorization as it increases perioperative risk
    Counseling recommendationPatients should be counseled on increased wound and reoperation risks associated with active tobacco use prior to elective reduction mammoplasty
    inv-27: Weight of breast tissue removed per breast — table values by BSA (appendix)
    Table scopeAppendix Table 1 lists weight of breast tissue to be removed per breast (grams) as a function of body surface area (BSA) from 1.40 to 2.20 m2
    Example low BSABSA 1.40 m2 → 324 g per breast
    Example mid BSABSA 1.50 m2 → 385 g per breast
    Upper-range valuesBSA values at and above ~1.92–2.00 m2 map to ~935–1000 g per breast, with many higher BSA entries set to 1000 g
    Use in determinationsTable is referenced in policy to determine if the surgeon's estimated tissue removal meets BSA-based gram thresholds for medical necessity
    inv-28: Body surface area → tissue weight per breast — BSA-to-grams table examples (appendix)
    BSA-to-grams mappingAppendix Table 1 provides the grams per breast corresponding to BSA values from 1.40 to 2.20 m2
    Calculation referencesBSA may be calculated using the Mosteller formula or alternative formulas provided in the appendix
    Selected examplesExamples: BSA 1.40 → 324 g; BSA 1.50 → 385 g; BSA 1.70 → 550–570 g depending on table entry
    Upper-limit representationFor higher BSA values the table lists values reaching 1000 g per breast (many entries capped at 1000 g)
    Clinical useThe BSA-to-grams table is intended to support preoperative estimates used in prior authorization and medical necessity determinations

    Provider Actions, Authorization & Documentation Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for covered reduction mammaplasty (CPT 19318) and related procedures. Coverage determinations are contingent on meeting the policy's selection criteria and supporting documentation.

    • Prior authorization required for CPT 19318 (reduction mammaplasty) and related covered codes.
    • Coverage contingent on meeting medical-necessity criteria and submission of required documentation (see appendices).
    Prior Authorization

    Assess Surgical Risk Factors During Authorization

    Authorization review must include assessment of preoperative surgical risk factors that influence complication rates and outcomes. Consider BMI, tobacco use, comorbidities (e.g., dyspnea), inpatient vs outpatient setting, age, and other factors that increase perioperative risk.

    • Evaluate BMI and obesity class (higher classes associated with increased complications).
    • Document active smoking status and counseling/cessation efforts.
    • Note whether procedure planned inpatient vs outpatient and assess dyspnea/other comorbidities.
    Documentation Required

    Use Appendix BSA-to-Tissue-Weight Table

    Use the Appendix BSA-to-tissue-weight Table (Table 1) to estimate the minimum grams of breast tissue expected to be removed per breast when applying tissue-weight thresholds for medical necessity.

    • Calculate body surface area (Mosteller formula) and reference Table 1 for the corresponding grams per breast.
    • If estimated removal per breast exceeds 1,000 g for medical necessity determinations, follow the policy notes in section I.
    Documentation Required

    Authorization Must Reference Policy Appendices

    Prior authorization must reference the policy criteria and supporting appendices. Submitted materials should explicitly cite the relevant appendix table(s) and grading scales used in the medical-necessity determination.

    • Reference Appendix Table 1 (BSA-to-grams) when tissue-weight thresholds are used.
    • Reference gynecomastia drug/exposure list (Appendix) and ASPS gynecomastia grade when applicable.
    Denial Risk

    Cosmetic Exclusions

    Procedures performed when policy indications are not met are considered cosmetic and are excluded from coverage. Reduction mammoplasty for asymptomatic members or for indications not listed as medically necessary is not covered.

    • Reduction mammaplasty for asymptomatic breasts or indications outside section I are cosmetic and excluded.
    • Gynecomastia surgery is considered cosmetic unless reversible causes have been evaluated and medical-necessity criteria are satisfied.
    Prior Authorization

    Timing Relative to Breast Maturity

    Delay authorization for adolescents until breast growth has ceased and size has been stable for at least 12 months; for adults, document that growth is complete when applicable.

    • For adolescents, confirm breasts stopped growing and size stable ≥ 12 months.
    • If growth not complete or stability not documented, authorization may be denied as premature.
    Denial Risk

    Irradiated Breast: Increased Complication Risk

    Reduction mammoplasty or mastopexy in previously irradiated breasts carries a substantially increased risk of complications. Authorization should document prior radiation and include detailed risk counseling; high-risk cases may be denied if expected complication risk is unacceptable.

    • Document history of ipsilateral breast irradiation and discuss increased complication rates.
    • Include surgeon assessment of risk/benefit and informed consent acknowledging higher complication rate in irradiated breast.
    Documentation Required

    Preoperative Documentation

    Preoperative documentation required with authorization includes the surgeon's estimate of tissue weight to be removed (per breast) based on BSA, high-quality frontal and side photographs, and clinical findings supporting symptomatic indications.

    • Surgeon-estimated grams to be removed per breast, calculated from BSA table (Mosteller formula).
    • High-quality color frontal and side-view photographs showing breast hypertrophy.
    • Clinical documentation linking symptoms to macromastia and prior conservative therapy trials.
    Documentation Required

    Tissue Weight and BSA Reference

    Providers must document body surface area (BSA), estimated tissue weight removed per breast (using Appendix Table 1), and gynecomastia grade when applicable; these elements are used to apply the policy thresholds.

    • BSA calculation method (Mosteller) and numeric BSA value.
    • Estimated grams removed per breast from Appendix Table 1.
    • Gynecomastia grade per ASPS scale when gynecomastia assessment is relevant.
    Documentation Required

    Medications and Exposures to Document for Gynecomastia

    For gynecomastia evaluation, document a detailed medication and exposure history and list drugs/exposures associated with gynecomastia. Correct reversible causes and consider medical therapy prior to surgical referral.

    • Include a complete drug history and environmental/occupational estrogen exposure assessment.
    • Document use of agents associated with gynecomastia (see Appendix drug list).
    • If reversible cause identified, document management (e.g., drug discontinuation) and response.
    Documentation Required

    Required Documentation Elements (See Appendices)

    Required documentation elements for authorization include completed conservative-therapy trial documentation, BSA and estimated tissue weight per breast, gynecomastia grade (if applicable), photos/imaging, and operative plan. When reduction is contralateral to cancer, submit histopathology documentation of the specimen per policy.

    • Documentation of ≥ 3-month trial of conservative therapies (analgesics/NSAIDs, physical therapy, supportive devices, dermatologic care, weight-loss program, specialist evaluations).
    • BSA calculation and estimated grams to be removed per breast (Appendix Table 1).
    • High-quality preoperative photographs and imaging as appropriate.
    • Gynecomastia grade (ASPS) and laboratory/imaging work-up if gynecomastia.
    • Histopathology report for contralateral reductions performed in the setting of breast cancer.
    Documentation Required

    Evaluation and Conservative Management Prior to Surgery

    Evaluation and conservative management must be completed prior to surgical consideration for gynecomastia. Work-up should include laboratory testing and imaging to identify reversible causes and a trial of medical/conservative therapy where appropriate.

    • Obtain detailed drug history, testicular exam, and labs (liver, thyroid, gonadotropins, hCG, testosterone, estradiol, DHEAS).
    • Imaging as indicated (testicular ultrasound, adrenal imaging) to identify lesions.
    • Treat reversible causes and document response; surgical removal is rarely indicated without failed conservative management.
    Step Therapy

    Consider Medical Therapy Trial for Gynecomastia

    A trial of medical therapy (e.g., tamoxifen) may be considered for idiopathic gynecomastia prior to surgery given evidence of high resolution rates; document duration, dose, and response.

    • Consider tamoxifen 10 mg daily trial and document clinical response and adverse effects.
    • If medical therapy leads to resolution, surgery is not indicated; if no response, include documentation of failed medical therapy when requesting authorization.

    Background and Context

    Reduction mammoplasty is a surgical procedure that removes excess breast tissue, glandular tissue, and skin to relieve symptoms associated with macromastia and to restore nipple position and breast contour. The operation is used to address functional symptoms (for example, back, neck, shoulder pain; bra-strap grooving; skin breakdown) and to improve quality of life in appropriately selected patients. [[11]]

    Definitions and Scales

    inv-47: Reduction mammoplasty — definition/key point
    DefinitionReduction mammoplasty (breast reduction) removes excess fat, glandular tissue, and skin to reduce breast volume and weight and to reposition the nipple and areola
    Goals of surgeryPrimary goals include symptom relief from heavy breasts, achieving a balanced appearance, maintaining lactation capacity, and allowing future breast exams with minimal scarring or decreased sensation
    TechniquesTraditional open reduction uses periareolar and inframammary incisions to excise tissue; liposuction-only techniques extract fat via a suction cannula through small incisions
    Cosmetic vs medicalReduction mammoplasty may be medically necessary when objective criteria are met; otherwise procedures performed solely for cosmetic indications are considered not medically necessary
    inv-48: Gigantomastia of pregnancy — definition and associated complications
    DefinitionGigantomastia of pregnancy is excessive breast enlargement during pregnancy accompanied by severe complications such as massive infection, significant hemorrhage, tissue necrosis with slough, or ulceration
    Coverage conditionCovered when any one of the listed complications is present and delivery is not imminent
    Clinical implicationSurgical management considered urgent in presence of these complications if maternal condition and timing of delivery permit
    inv-49: Gynecomastia — definition and classification
    DefinitionGynecomastia is development of subareolar breast tissue in males, commonly transient in adolescence
    ClassificationType I (idiopathic): tender, firm subareolar mass, often unilateral; Type II: more generalized breast enlargement
    EpidemiologyUp to 60–70% of adolescent males develop transient gynecomastia during Tanner stages II–III
    Associated causesCan be caused by hormonal imbalance, endocrine tumors, liver or thyroid dysfunction, and drug exposures
    inv-50: Pseudo-gynecomastia — definition (adipose-driven enlargement)
    DefinitionPseudo-gynecomastia refers to breast enlargement due to excessive adipose tissue or prominent pectoralis muscles rather than glandular proliferation
    Distinguishing featuresPseudo-gynecomastia lacks the firm subareolar glandular tissue seen in true gynecomastia on physical exam
    Implication for managementIdentification of pseudo-gynecomastia may shift management toward weight loss or liposuction rather than gland excision
    inv-51: Body surface area (BSA) — definition and calculation methods
    Definition and useBody surface area (BSA) is calculated (Mosteller or alternative formula) and used to estimate expected grams of breast tissue to be removed per breast via Appendix Table 1
    Mosteller formula referenceBSA may be calculated with the Mosteller method or using the provided height/weight formulas in the appendix
    Purpose in policyBSA-based estimates inform whether the planned resection meets the policy's gram thresholds for medical necessity
    Calculator linkPolicy references an online BMI and BSA (Mosteller) calculator for ease of calculation
    inv-52: Drug-associated gynecomastia — exposures and mechanism categories
    Exposure categoriesDrugs and exposures associated with gynecomastia include: estrogens and estrogen-like agents; drugs that enhance estrogen formation (eg, hCG); drugs that inhibit testosterone synthesis (eg, ketoconazole, spironolactone); and drugs that inhibit testosterone action (eg, bicalutamide, finasteride)
    Other implicated agentsAdditional associated medications include tricyclic antidepressants, ACE inhibitors, amiodarone, anabolic steroids, and topical agents containing lavender or tea tree oil
    Clinical actionMedication and exposure history should be reviewed and documented during gynecomastia evaluation to identify reversible causes
    inv-53: ASPS Gynecomastia Scale — Grade II–III descriptions
    Grade II descriptionGrade II: Moderate breast enlargement exceeding areola boundaries with edges that are indistinct from the chest
    Grade III descriptionGrade III: Moderate enlargement exceeding areola boundaries with edges indistinct from the chest and with skin redundancy present
    Grade IV descriptionGrade IV: Marked breast enlargement with skin redundancy and feminization of the breast
    Use in documentationProviders should document ASPS grade when submitting gynecomastia cases for review as part of required documentation elements

    Policy Revision History

    2023-03-06reviewLatest

    Policy last reviewed (clinical content reviewed).

    1995-10-06effective

    Policy original effective date recorded as 1995-10-06.